Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 638,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $60,375,372
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 57
End Date 2024-01-21 2023-10-20 2023-04-21 2022-04-21

   
Records found: 1213
  Page 8 of 49  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-05-01 4 S $64.42 $1,803,897 D/D (28,000) 33,000     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-05-01 4 OE $39.06 $1,093,680 D/D 28,000 61,000     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-04-30 4 A $22.21 $20,340 D/D 916 45,505     -
   Wood Mark VP, Human Resources   •       –      –    2013-04-30 4 A $27.91 $16,603 D/D 595 23,840     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-04-30 4 A $23.21 $18,680 D/D 805 53,155     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-04-30 4 A $23.21 $19,910 D/D 858 47,058     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-04-30 4 A $23.21 $13,482 D/D 581 13,860     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-04-30 4 A $23.20 $18,490 D/D 797 11,367     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-04-30 4 S $63.74 $63,742 D/D (1,000) 119,317     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-04-30 4 A $23.21 $21,256 D/D 916 120,317     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-04-30 4 S $63.29 $1,265,800 D/D (20,000) 44,589     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-04-30 4 OE $11.05 $221,000 D/D 20,000 64,589     -
   Wood Mark VP, Human Resources   •       –      –    2013-04-22 4 AS $65.57 $203,413 D/D (3,102) 23,245     -
   Wood Mark VP, Human Resources   •       –      –    2013-04-22 4 OE $14.39 $72,390 D/D 3,102 26,347     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-04-19 4 AS $65.00 $325,000 D/D (5,000) 10,570     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-04-19 4 OE $21.51 $107,550 D/D 5,000 15,570     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-04-10 4 AS $64.00 $1,280,000 D/D (20,000) 52,350     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-04-10 4 OE $14.39 $287,800 D/D 20,000 72,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-03-26 4 AS $60.68 $728,147 I/I (12,000) 13,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-03-26 4 OE $12.99 $155,880 I/I 12,000 25,545     -
   Wood Mark VP, Human Resources   •       –      –    2013-03-22 4 AS $60.21 $186,821 D/D (3,103) 23,245     -
   Wood Mark VP, Human Resources   •       –      –    2013-03-22 4 OE $14.39 $72,405 D/D 3,103 26,348     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-03-20 4 A $61.43 $556 D/D 9 68,699     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-03-18 4 A $61.38 $860 D/D 14 68,690     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-03-18 4 AS $61.02 $1,220,360 D/D (20,000) 52,350     -
  1213 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 49
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us